PROFILE OF ADVERSE DRUG REACTIONS OF ANTIRETROVIRAL USE IN HIV/AIDS PATIENTS IN VCT POLYCLINIC IN MATARAM CITY IN 2019
DOI:
https://doi.org/10.29303/jku.v9i4.443Keywords:
HIV infection, ARV, Atripla, Duviral/Neviral, side effects, first degreeAbstract
Background: In treating HIV infection, Indonesia uses the fast track 90-90-90 approach, which one indicator is giving early ARV treatment to infected patients. First line ARV used in Indonesia today is a fixed-dose combination (FDC) consisting of tenofovir, lamivudine/emtricitabine, and efavirenz. ARV use might cause adverse drug reactions (ADR) with ADR range from mild to severe in HIV patients. This research aims to identify the adverse drug reactions caused by ARV in HIV/AIDS patients in VCT Polyclinic in Mataram City in 2019.
Methods: This research is a quantitative descriptive study done in VCT Polyclinic in Mataram city. The subjects are HIV patients in VCT Polyclinic in Mataram city who had met the criteria. This research used secondary data from patients’medical records.
Result: Total subjects are 27 patients. ADR occurred in 8 patients (29.6%). These ADR were found in 7 patients using atripla with malaise, dizziness, vomiting, and increased SPOT/SGPT being the most common ADR. One patient using duviral/neviral were found with nausea, vomiting, and itchiness. These ADR came 100% from first degree drug toxicity.
Conclusion: The most common ADR were vomiting, malaise, dizziness, and increased SGOT/SGPT. All adverse drug reactions were mild (first degree) therefore therapy was continued and there was no need to consider switching treatment.
Keywords: HIV infection, ARV, Atripla, Duviral/Neviral, side effects, first degree
References
2. Menteri Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/90/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana HIV. Kementrian Kesehatan Republik Indonesia; Jul, 2019.
3. Anwar Y, Nugroho SA, Wulandari SD. Profile Of Antiretroviral Side Effects On Hiv In Rspi Prof. Dr. Sulianti Saroso Jakarta. J Ilmu Kefarmasian Indones. 2018;16(1):49.
4. Menteri Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 87 Tahun 2014 Tentang Pedoman Pengobatan Antiretroviral. 2014.
5. Montessori V, Press N, Harris M, Akagi L, Montaner JSG. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004 Jan;170(2):229–38.
6. Puspasari D, Wisaksana R, Ruslami R. Gambaran Efek Samping dan Kepatuhan Terapi Antiretroviral pada Pasien HIV di Rumah Sakit Dr. Hasan Sadikin Bandung Tahun 2015. Vol. 3, JSK. 2018.
7. Ibrahim SA, Sabitu K, Abubakar A, Poggensee G, Ibrahim S, Riyad M, Bashorun A, Sudawa AU, Ibrahim BS, Mohammed H, Ezeudu C, Abubakar AA, Nsubuga P, Nguku P. Demographic factors associated with HIV infection between low and high prevalence areas in Nigeria, 2015. Pan Afr Med J. 2019;32(Supp 1):11.
8. Freeman E, Anglewicz P. HIV prevalence and sexual behaviour at older ages in rural Malawi. Int J STD AIDS [Internet]. 2012 Jul;23(7):490–6. Available from: http://journals.sagepub.com/doi/10.1258/ijsa.2011.011340
9. Malalur C, Shenoy S, Varma M, Kamath A, Manohar H, Saravu K. Evaluation of adverse drug reaction profile of antiretrovirals in HIV-positive patients in a tertiary care hospital. Natl J Physiol Pharm Pharmacol [Internet]. 2016;6(5):488. Available from: http://www.scopemed.org/fulltextpdf.php?mno=230561
10. Abah IO, Ncube NBQ, Bradley HA, AgbaJi OO, Kanki P. Antiretroviral Therapy-associated Adverse Drug Reactions and their Effects on Virologic Failure- A Retrospective Cohort Study in Nigeria. Curr HIV Res. 2019;16(6):436–46.
11. Akinyemi JO, Ogunbosi BO, Fayemiwo AS, Adesina OA, Obaro M, Kuti MA, Awolude OA, Olaleye DO, Adewole IF. Demographic and epidemiological characteristics of HIV opportunistic infections among older adults in Nigeria. Afr Health Sci. 2017;17(2):315–21.
12. The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Cd4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: A longitudinal cohort study from COHERE. PLoS Med. 2012;9(3).
13. Ford N, Meintjes G, Vitoria M, Greene G, Chiller T. The evolving role of CD4 cell counts in HIV care. Curr Opin HIV AIDS [Internet]. 2017 Mar;12(2):123–8. Available from: https://journals.lww.com/01222929-201703000-00005
14. Hagos L, Fessehaye S, Anand IS. Nature and prevalence of adverse drug reaction of antiretroviral medications in Halibet National Referral Hospital: A retrospective study. BMC Pharmacol Toxicol. 2019;20(1):1–7.
15. Julg B, Bogner JR. Atriplatrade mark - HIV therapy in one pill. Ther Clin Risk Manag [Internet]. 2008 Jun;4(3):573–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18827852
16. Akshaya Srikanth B, Chandra Babu S, Yadav HN, Jain SK. Incidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapy. J Adv Pharm Technol Res. 2012;3(1):62–7.
17. Anderson PL, Rower JE. Zidovudine and Lamivudine for HIV Infection. Clin Med Rev Ther. 2010;2:115–27.
18. Ena J, Amador C, Benito C, Pasquau F. Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations. Vol. 4, HIV/AIDS - Research and Palliative Care. 2012. p. 169–79.
19. Mukherjee S, Era N, Saha B, Tripathi S. Adverse drug reaction monitoring in patients on antiretroviral therapy in a tertiary care hospital in Eastern India. Indian J Pharmacol [Internet]. 2017;49(3):223. Available from: http://www.ijp-online.com/text.asp?2017/49/3/223/215726
20. Alomar MJ. Factors affecting the development of adverse drug reactions ( Review article ). Saudi Pharm J [Internet]. 2014;22(2):83–94. Available from: http://dx.doi.org/10.1016/j.jsps.2013.02.003
21. Eluwa GI, Badru T, Akpoigbe KJ. Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. BMC Clin Pharmacol. 2012 Dec;12(1):7.
22. Sari SP, Isnaini SRi, Puspitasari AW. Monitoring Side Effects Of Antiretroviral Therapy In Patients With Human Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome. Int J Appl Pharm. 2018;10(1).
